Skin disease biotech Processa Pharmaceuticals files for a $16 million Nasdaq IPO - (NASDAQ via NewsPoints Desk)

  • Processa Pharmaceuticals filed with the SEC to raise up to $16 million in an initial public offering, as reported NASDAQ.

  • The company, which is developing an analog therapy for necrotic skin disease, plans to list on the Nasdaq under the symbol PCSA.

  • Pricing terms were not disclosed.

To read more NewsPoints articles, click here.